Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-09-09), Aquestive Therapeutics's 6-1 Month Momentum % is -8.16%.
The industry rank for Aquestive Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
AQST's 6-1 Month Momentum % is ranked worse than 50.2% of 1024
companies
in the Drug Manufacturers industry
Industry Median: -6.49
vs AQST: -8.16
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Aquestive Therapeutics 6-1 Month Momentum % Related Terms
AQST vs TLRY, EOLS, IRWD: 6-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics 6-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquestive Therapeutics (AQST) has a 6-1 Month Momentum % of -8.16% as of Sep. 09, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Aquestive Therapeutics and its competitors. According to the industry distribution chart, Aquestive Therapeutics ranks #514 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 50.2%.
Is Aquestive Therapeutics' 6-1 Month Momentum % too high?
Aquestive Therapeutics' current 6-1 Month Momentum % is -8.16%. Based on the distribution chart, Aquestive Therapeutics ranks #514 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' 6-1 Month Momentum % compare to TLRY and EOLS?
According to the Drug Manufacturers industry distribution chart, Aquestive Therapeutics ranks #514 out of 1024 companies for 6-1 Month Momentum %. This places Aquestive Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Drug Manufacturers company?
A good 6-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Aquestive Therapeutics and its competitors. Aquestive Therapeutics's current 6-1 Month Momentum % is -8.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current 6-1 Month Momentum % is -8.16%. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current 6-1 Month Momentum % is -8.16% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aquestive Therapeutics (AQST) Overvalued in 2026?
Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued.
The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37.
GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.
Key valuation signals for AQST:
6-1 Month Momentum %: -8.16%
GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score
Get the complete analysis for AQST
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQST has been successfully added to your 
